Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19
In a randomized control trial on convalescent plasma therapy (CPT) in severe COVID-19, we characterized the nature, in terms of abundance of forty eight cytokines, and dimensions, in terms of their interrelationships, of the hyper-immune activation-associated ‘cytokine storm’ in patients suffering from acute respiratory distress syndrome. We found reduced plasma level of the chemokine MCP3 to be a key correlate for clinical improvement, irrespective of therapeutic regimen. We also identified an anti-inflammatory role of CPT independent of its neutralizing antibody content, and a linear regression analysis revealed that neutralizing antibodies as well as the anti-inflammatory effect of CPT both contribute to marked immediate reductions in hypoxia, as compared to patients on standard therapy..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
bioRxiv.org - (2021) vom: 16. Feb. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bandopadhyay, Purbita [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.1101/2020.09.21.20199109 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI018805027 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI018805027 | ||
| 003 | DE-627 | ||
| 005 | 20230429100304.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200924s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.09.21.20199109 |2 doi | |
| 035 | |a (DE-627)XBI018805027 | ||
| 035 | |a (DE-599)biorXiv10.1101/2020.09.21.20199109 | ||
| 035 | |a (biorXiv)10.1101/2020.09.21.20199109 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Bandopadhyay, Purbita |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a In a randomized control trial on convalescent plasma therapy (CPT) in severe COVID-19, we characterized the nature, in terms of abundance of forty eight cytokines, and dimensions, in terms of their interrelationships, of the hyper-immune activation-associated ‘cytokine storm’ in patients suffering from acute respiratory distress syndrome. We found reduced plasma level of the chemokine MCP3 to be a key correlate for clinical improvement, irrespective of therapeutic regimen. We also identified an anti-inflammatory role of CPT independent of its neutralizing antibody content, and a linear regression analysis revealed that neutralizing antibodies as well as the anti-inflammatory effect of CPT both contribute to marked immediate reductions in hypoxia, as compared to patients on standard therapy. | ||
| 700 | 1 | |a D’Rozario, Ranit |e verfasserin |4 aut | |
| 700 | 1 | |a Lahiri, Abhishake |e verfasserin |4 aut | |
| 700 | 1 | |a Sarif, Jafar |e verfasserin |4 aut | |
| 700 | 1 | |a Ray, Yogiraj |e verfasserin |4 aut | |
| 700 | 1 | |a Paul, Shekhar Ranjan |e verfasserin |4 aut | |
| 700 | 1 | |a Roy, Rammohan |e verfasserin |4 aut | |
| 700 | 1 | |a Maiti, Rajshekhar |e verfasserin |4 aut | |
| 700 | 1 | |a Chaudhuri, Kausik |e verfasserin |4 aut | |
| 700 | 1 | |a Bagchi, Saugata |e verfasserin |4 aut | |
| 700 | 1 | |a Maiti, Ayan |e verfasserin |4 aut | |
| 700 | 1 | |a Perwez, Md. Masoom |e verfasserin |4 aut | |
| 700 | 1 | |a Sarkar, Biswanath Sharma |e verfasserin |4 aut | |
| 700 | 1 | |a Roy, Devlina |e verfasserin |4 aut | |
| 700 | 1 | |a Chakraborty, Rahul |e verfasserin |4 aut | |
| 700 | 1 | |a Vasudevan, Janani Srinivasa |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Sachin |e verfasserin |4 aut | |
| 700 | 1 | |a Biswas, Durba |e verfasserin |4 aut | |
| 700 | 1 | |a Maiti, Chikam |e verfasserin |4 aut | |
| 700 | 1 | |a Saha, Bibhuti |e verfasserin |4 aut | |
| 700 | 1 | |a Bhattacharya, Prasun |e verfasserin |4 aut | |
| 700 | 1 | |a Pandey, Rajesh |e verfasserin |4 aut | |
| 700 | 1 | |a Chatterjee, Shilpak |e verfasserin |4 aut | |
| 700 | 1 | |a Paul, Sandip |e verfasserin |4 aut | |
| 700 | 1 | |a Ganguly, Dipyaman |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 16. Feb. |
| 773 | 1 | 8 | |g year:2021 |g day:16 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.09.21.20199109 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 16 |c 02 | ||
| 953 | |2 045F |a 570 | ||